TCR Gene Therapy in Pancreatic Cancer | NEJM
Pancreatic cancer is resistant to most forms of therapy but may be vulnerable to T cells that recognize a “hot-spot” mutation — KRAS G12D — commonly found in that cancer. New research findings are summarized in a short video.
To see the full article, follow this link: https://nej.md/3wS9STm
